CDH17 and colorectal carcinoma: MSLN, MUC1, placental alkaline phosphatase (PLAP), c-MET, and Cadherin-17 (CDH17) are also promising targets in CAR-T cell therapies for CRC, validated in several preclinical trials [251–255] (Fig. 3).